Screening and clinical implications for BRCA1 and BRCA2 mutation carriers (Q33923799)

30 July 2017

1 reference

title

Screening and clinical implications for BRCA1 and BRCA2 mutation carriers (English)

1 reference

30 July 2017

1 reference

1 reference

Plon SE

1

1 reference

30 July 2017

publication date

1 October 1998

1 reference

Journal of Mammary Gland Biology and Neoplasia

30 July 2017

published in

1 reference

30 July 2017

volume

3

1 reference

30 July 2017

issue

4

1 reference

30 July 2017

page(s)

377-387

1 reference

The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals

30 July 2017

cites work

1 reference

12 December 2020

Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region.

1 reference

12 December 2020

Screening for 185delAG in the Ashkenazim

1 reference

12 December 2020

Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

1 reference

12 December 2020

Prognosis of BRCA1 hereditary breast cancer

1 reference

12 December 2020

Genetic testing: employability, insurability, and health reform.

1 reference

12 December 2020

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium

1 reference

12 December 2020

Differential Contributions ofBRCA1andBRCA2to Early-Onset Breast Cancer

1 reference

12 December 2020

Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene

1 reference

12 December 2020

Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996

1 reference

12 December 2020

Psychologic aspects of cancer genetic testing: a research update for clinicians

1 reference

12 December 2020

Genetic counseling for families with inherited susceptibility to breast and ovarian cancer

1 reference

12 December 2020

BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing.

1 reference

12 December 2020

Women's receptivity to testing for a genetic susceptibility to breast cancer

1 reference

12 December 2020

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews

1 reference

12 December 2020

Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families

1 reference

12 December 2020

Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families

1 reference

12 December 2020

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually

1 reference

12 December 2020

Role of prophylactic surgery for women with genetic predisposition to cancer

1 reference

12 December 2020

NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer

1 reference

12 December 2020

BRCA1--lots of mutations, lots of dilemmas

1 reference

12 December 2020

The influence of psychological distress on use of genetic testing for cancer risk

1 reference

12 December 2020

Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium

1 reference

12 December 2020

A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening

1 reference

12 December 2020

BRCA-associated breast cancer in young women

1 reference

12 December 2020

Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1.

1 reference

12 December 2020

What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing

1 reference

12 December 2020

Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes?

1 reference

12 December 2020

Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.

1 reference

12 December 2020

Breast cancer genes--what are the real risks?

1 reference

12 December 2020

BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes

1 reference

12 December 2020

Genetic information and the workplace: legislative approaches and policy changes.

1 reference

12 December 2020

The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%

1 reference

12 December 2020

Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations ofBRCA1

1 reference

12 December 2020

Prophylactic oophorectomy in inherited breast/ovarian cancer families

1 reference

12 December 2020

Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.

1 reference

12 December 2020

Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients

1 reference

12 December 2020

The use and interpretation of commercial APC gene testing for familial adenomatous polyposis

1 reference

12 December 2020

Phenocopies versus genetic heterogeneity: can we use phenocopy frequencies in linkage analysis to compensate for heterogeneity?

1 reference

12 December 2020

Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.

1 reference

12 December 2020

BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer

1 reference

12 December 2020

Statement of the American Society of Human Genetics on genetic testing for breast and ovarian cancer predisposition

1 reference

12 December 2020

BRCA1, pathology, and survival

1 reference

12 December 2020

Genetic testing for cancer risk: how to reconcile the conflicts.

1 reference

12 December 2020

An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium.

1 reference

12 December 2020

Effect of Smoking on Breast Cancer in Carriers of Mutant BRCA1 or BRCA2 Genes

1 reference

12 December 2020

Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus

1 reference

12 December 2020

The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women

1 reference

12 December 2020

Linkage of early-onset familial breast cancer to chromosome 17q21

1 reference

12 December 2020

Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden

1 reference

12 December 2020

Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2

1 reference

12 December 2020

Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer

1 reference

12 December 2020

Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage

1 reference

12 December 2020

Population genetics of BRCA1 and BRCA2.

1 reference

12 December 2020

Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women?

1 reference

12 December 2020

Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1018731914813

1 reference

Dimensions Publication ID

30 July 2017

1019452492

0 references

1 reference